Michael George Hunter

Title: Michael George Hunter: Innovator in CRTH2-Mediated Disease Treatments

Introduction

Michael George Hunter, an accomplished inventor based in Abingdon, GB, has made significant contributions to the field of pharmaceutical innovation. With a total of five patents to his name, Hunter focuses on the treatment of diseases mediated by the CRTH2 pathway. His work exemplifies the intersection of science and innovation, and highlights his commitment to advancing medical treatments.

Latest Patents

Among Hunter’s notable innovations is his latest patent addressing the treatment of CRTH2-mediated diseases and conditions. This invention provides indole derivatives that antagonize prostaglandin D, which can be used to treat various inflammatory diseases linked to prostaglandin D activity. This groundbreaking work is aimed at improving patient outcomes in inflammatory disorders.

Career Highlights

Michael George Hunter is significantly affiliated with Oxagen Limited, a company dedicated to innovative research and development in the pharmaceutical sector. His involvement with Oxagen has been instrumental in driving forward the therapeutic possibilities for treating CRTH2-mediated diseases.

Collaborations

During his career, Hunter has collaborated with esteemed colleagues such as David Middlemiss and Mark Richard Ashton. Their collective expertise and shared vision have propelled advancements in their research initiatives and fostered a productive environment for innovation.

Conclusion

Michael George Hunter's contributions to the field of medical innovation, particularly in the realm of CRTH2-mediated treatments, underscore his role as a key inventor. His work at Oxagen Limited, along with collaborative efforts with fellow researchers, paves the way for future advancements in the treatment of inflammatory diseases. Hunter's patents not only reflect his ingenuity but also embody the promise of improved healthcare solutions.